Show simple item record

dc.contributor.authorKass, Lindsy
dc.contributor.authorRosanoff, Andrea
dc.contributor.authorTanner, Amy
dc.contributor.authorMcAuley, William
dc.contributor.authorSullivan, Keith
dc.contributor.authorPlesset, Michael
dc.date.accessioned2018-01-24T13:50:58Z
dc.date.available2018-01-24T13:50:58Z
dc.date.issued2017-04-12
dc.identifier.citationKass , L , Rosanoff , A , Tanner , A , McAuley , W , Sullivan , K & Plesset , M 2017 , ' Effect of Transdermal Magnesium Cream on Serum and Urinary Magnesium Levels in Humans: A Pilot Study ' , PLoS ONE , vol. 12 , no. 4 , e0174817 . https://doi.org/10.1371/journal.pone.0174817
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/2299/19606
dc.description© 2017 Kass et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.description.abstractBackground Oral magnesium supplementation is commonly used to support a low magnesium diet. This investigation set out to determine whether magnesium in a cream could be absorbed transdermally in humans to improve magnesium status. Methods and findings In this single blind, parallel designed pilot study, n=25 participants (aged 34.3+/-14.8y, height 171.5+/-11cm, weight 75.9 +/-14 Kg) were randomly assigned to either a 56mg/day magnesium cream or placebo cream group for two weeks. Magnesium serum and 24hour urinary excretion were measured at baseline and at 14 days intervention. Food diaries were recorded for 8 days during this period. Mg test and placebo groups’ serum and urinary Mg did not differ at baseline. After the Mg2+ cream intervention there was a clinically relevant increase in serum magnesium (0.82 to 0.89 mmol/l,p=0.29) that was not seen in the placebo group (0.77 to 0.79 mmol/L), but was only statistically significant (p=0.02)) in a subgroup of non-athletes . Magnesium urinary excretion increased from baseline slightly in the Mg2+ group but with no statistical significance (p=0.48). The Mg2+ group showed an 8.54% increase in serum Mg2+ and a 9.1% increase in urinary Mg2+ while these figures for the placebo group were smaller, i.e. +2.6% for serum Mg2+ and -32% for urinary Mg2+. In the placebo group, both serum and urine concentrations showed no statistically significant change after the application of the placebo cream. Conclusion No previous studies have looked at transdermal absorbency of Mg2+ in human subjects. In this pilot study, transdermal delivery of 56 mg Mg/day (a low dose compared with commercial transdermal Mg2+ products available) showed a larger percentage rise in both serum and urinary markers from pre to post intervention compared with subjects using the placebo cream, but statistical significance was achieved only for serum Mg2+ in a subgroup of non-athletes. Future studies should look at higher dosage of magnesium cream for longer durations.en
dc.format.extent11
dc.format.extent1026755
dc.language.isoeng
dc.relation.ispartofPLoS ONE
dc.titleEffect of Transdermal Magnesium Cream on Serum and Urinary Magnesium Levels in Humans: A Pilot Studyen
dc.contributor.institutionExercise, Health and Wellbeing Research Group
dc.contributor.institutionHigh Performance Sport Research Group
dc.contributor.institutionDepartment of Psychology, Sport and Geography
dc.contributor.institutionCentre for Agriculture, Food and Environmental Management Research
dc.contributor.institutionCentre for Research in Psychology and Sport Sciences
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionFood Policy, Nutrition and Diet
dc.contributor.institutionAgriculture, Food and Veterinary Sciences
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionSkin and Nail Group
dc.contributor.institutionPharmaceutics
dc.contributor.institutionPharmaceutical Analysis and Product Characterisation
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionHealth Research Methods Unit
dc.contributor.institutionApplied Psychology Research Group
dc.contributor.institutionHealth and Clinical Psychology Research Group
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.description.statusPeer reviewed
dc.identifier.urlhttp://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0174817&type=printable
rioxxterms.versionofrecord10.1371/journal.pone.0174817
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record